This is a patient with atopic dermatitis, treated with topicals (steroids and topical calcineurin inhibitors), bleach baths, anti-histamines, phototherapy, systemic steroids, cyclosporine, and Dupixent. His provider is requesting continuation of Dupixent. The health plan's determination is overturned. This patient has severe eczema and has failed other standard of care therapies for atopic dermatitis. According to the clinic notes the patient has done phototherapy in the past which did not help, and was placed on cyclosporine. The safety and efficacy were supported in a recent meta-analysis of all published dupilumab paper. Dupixent in this patient is in accordance with Generally Accepted Standards of Medical Practice, clinically appropriate, in terms of type, frequency, extent, site of Service, duration, and considered effective, and can be considered more effective than other therapies as this patient has already failed other standard treatment options.